1. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, MD, Anna F. Farago, MD, Filippo de Braud, MD, Akin Atmaca, MD, Matthew D. Hellmann, MD, Jeffrey G. Schneider, MD, David R. Spigel, MD, Victor Moreno, MD, Ian Chau, MD, Christine L. Hann, MD, Joseph Paul Eder, MD, Nicola L. Steele, MBChB, PhD, Anne Pieters, MS, Justin Fairchild, MPH, Scott J. Antonia, MD 
Journal of Thoracic Oncology 
Volume 14, Issue 2, Pages (February 2019)
DOI: /j.jtho
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Duration of response (DOR) by blinded independent central review with third- or later-line (3L+) nivolumab monotherapy. CI, confidence interval.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Progression-free survival (PFS) by blinded independent central review with third- or later-line (3L+) nivolumab monotherapy. CI, confidence interval.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Overall survival (OS) with third- or later-line (3L+) nivolumab monotherapy. CI, confidence interval.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions